- Home
- ANTX vs XCUR Comparison
ANTX vs XCUR Comparison
Compare ANTX & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.30
HOLD
Current Price
$6.23
Company Overview
Basic Information| Metric | ANTX | XCUR |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.2M | 26.6M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANTX | XCUR |
|---|---|---|
| Price | $1.30 | $6.23 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 117.3K | 64.6K |
| Earning Date | 11-12-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $3.10 |
| 52 Week High | $1.55 | $15.91 |
Technical Indicators
Market Signals| Indicator | ANTX | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 61.15 | N/A |
| Support Level | $1.13 | N/A |
| Resistance Level | $1.35 | N/A |
| Average True Range (ATR) | 0.10 | 0.00 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 88.60 | 0.00 |
Price Performance
Historical Comparison ANTX
XCUR
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.